AptarGroup reported a 9% increase in sales to $845 million, with core sales up 13%. The company experienced double-digit core sales growth in each segment. Reported earnings per share were $0.93, and adjusted earnings per share were $0.96.
Reported sales grew 9% and core sales grew 13% with double-digit core growth in each segment.
Pharma segment posted sales growth in all markets including the prescription drug division as demand for allergic rhinitis and asthma devices began to recover.
Reported earnings per share of $0.93 compared to $1.24 in the prior year.
Adjusted earnings per share of $0.96 compared to $1.05 in the prior year.
Aptar expects earnings per share for the second quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.92 to $1.02.
Visualization of income flow from segment revenue to net income